Protalex Inc

Protalex — Investor Presentation (September 2013)

20 slides from Protalex's investor presentation, Sep 5, 2013

  1. Slide 1: September, 2013

    September, 2013

  2. Slide 2: Forward-Looking Statement

    Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The company ’ s actual results could differ materially from those projected. Additional information is contained in the company ’ s SEC fil

  3. Slide 3: Protalex, Inc.

    Protalex , Inc. Biotechnology company focused on autoimmune diseases Market cap: recently $75 mm; 30 mm SOS Public company (OTC BB: PRTX) ▪ Current ownership and management structure established in November 2009 ▪ Niobe Ventures, LLC, has invested $14 mm since 2009 and controls 79% of the equity Lea

  4. Slide 4: Investment Highlights

    Investment Highlights PRTX - 100 is a novel immunomodulatory biological drug candidate that may be useful in the treatment of a variety of autoimmune diseases Proof - of - concept data from ongoing phase 1b trial in rheumatoid arthritis patients expected in early 2014 Potential efficacy in a number

  5. Slide 5: Background

    PRTX - 100 Background Highly purified Staphylococcus aureus protein A (SPA) 42 kDa bacterial membrane protein comprising five homologous 58 – 61 amino acid immunoglobulin binding domains ▪ Binds to Fc region of IgG ▪ Binds with high affinity to F ab framework region of Clade VH3 Igs (most autoantibo

  6. Slide 6: Reduces Footpad Swelling in Murine Collagen Induced Arthritis Model

    PRTX - 100 Reduces Footpad Swelling in Murine Collagen Induced Arthritis Model Paw Thickness 0 0.2 0.4 0.6 0.8 1 1.2 28 31 35 38 42 45 49 52 56 Days After Immunization Thickness Change (mm) ▪ Female DBA/1 mice immunized with bovine collagen II, boost with CII on d21 ▪ Treat with PRTX - 100 (3x/ wk 0

  7. Slide 7: Is Not Immunosuppressive Like Anti-TNFs

    PRTX - 100 Is Not I mmunosuppressive L ike A nti - TNFs Anti - TNF biologics can increase susceptibility to systemic infections by fungal pathogens, listeria, and tuberculosis FDA “Black Box” warning We treated mice with PRTX - 100, Etanercept , rabbit anti - mouse TNF, or vehicle and challenged wit

  8. Slide 8: PRTX-100 Inhibits Platelet Phagocytosis by Human Macrophages in vitro

    PRTX - 1oo Inhibits Platelet Phagocytosis by Human M acrophages in vitro In ideopathic thrombocytopenic purpura , platelets are opsonized by autoantibodies and phagocytized by macrophages in an FC g R - dependent process In this model , PRTX - 100 down - regulates FC g RI (CD16), a receptor known to

  9. Slide 9: Therapeutic Hypothesis and Key Points

    PRTX - 100 Therapeutic Hypothesis and Key Points PRTX - 100 is an immune modulator that acts through mechanisms targeting activated macrophages and certain B - cells; it is not an immunosuppressant like TNF - inhibitors or anti - CD20s PRTX - 100 is derived from fermentation of non - recombinant bac

  10. Slide 10: Autoimmune Disease Market Opportunity

    Autoimmune Disease Market Opportunity RA biologicals current market value exceeds $18 B and is growing RA market disruptions envisioned ▪ PFE’s Xeljanz ( tofacitinib ) oral drug recently approved ▪ Bioequivalents to anti - TNFs and anti - CD20s in development High value/ lower cost modalities may ex

  11. Slide 11: Potential for Orphan Drug Designation

    PRTX - 100 Potential for Orphan Drug Designation Adult idiopathic thrombocytopenic purpura (ITP) ▪ Incidence: 20 - 30 cases/million per year; patients with platelet counts > 25,000 are rarely treated, so few require aggressive treatment ▪ Treatments include steroids, splenectomy , thrombopoietin ago

  12. Slide 12: Clinical Experience

    PRTX - 100 Clinical Experience 2005 – IND filed for RA 2006 – Phase 1 study completed 2007 – Second Phase 1 using PRTX - 100 with improved production/CMC processes 2010 - 11 – Phase 1b Study (PRTX - 100 - 103) in South Africa; presented at ACR Annual Meeting in November, 2012 November 2012 – Second

  13. Slide 13: 103: Study Objectives

    PRTX - 100 - 103: Study Objectives Primary ▪ Assess safety and tolerability of iv PRTX - 100 weekly x 4 doses Secondary ▪ Assess immunogenicity after ≥3 doses ▪ Determine PK and estimate of PRTX - 100 plasma exposure after first and fourth dose ▪ Determine whether a relationship exists between immun

  14. Slide 14: 103: Study Design

    PRTX - 100 - 103: Study Design Week: 0 1 2 3 6 4 10 8 12 16 Dosing: ACR & DAS assessments: Anti - SPA ABS: 90 days PK profile: CBC, CHEM,U/ A: Sequential Cohorts (8 active: 2 Placebo) randomized to receive 0.15, 0.45, 0.9, or 1.5 m g/kg PRTX - 100 i.v. 14 Protalex

  15. Slide 15: 103: DAS28 < 3.2

    PRTX - 100 - 103: DAS28 < 3.2 0 5 10 15 20 25 30 PRTX-100 Placebo % of patients with DAS28 < 3.2 at 6 and 10 weeks Day 42 Day 70 3/29 6/29 0/8 0/8 15 Protalex , Inc.

  16. Slide 16: 103: Summary

    PRTX - 100 - 103: Summary PRTX - 100 was well tolerated ▪ 3 mild to moderate infusion reactions, no SAEs related to study drug ▪ Anti - PRTX - 100 antibodies elicited in majority of patients but neither incidence nor titer was related to dose ▪ Patients with antibody response showed increased cleara

  17. Slide 17: 104: Overview

    PRTX - 100 - 104 : Overview New multi - center US study. Phase 1b randomized, multiple - dose, placebo - controlled, dose - escalation study of PRTX - 100 in adults with active RA on MTX Recent amendment calls for up to 44 patients in four dose - escalating cohorts, starting at 1.50 m g/kg, with fif

  18. Slide 18: Patents and Intellectual Property

    Patents and Intellectual Property Patents (five issued in US and Japan) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 ▪ Issued continuation patents expanding use to various inflammatory diseases filed 2004, 2006, and 2010; notice of allowance f

  19. Slide 19: Protalex Objectives

    Protalex Objectives x 2Q13 Safety data from first three cohorts of PRTX - 100 - 104 □ 3Q13 Initiation of cohort 5 extension study, to investigate monthly maintenance doses □ 4Q13 Filing IND for PRTX - 100 in orphan indication □ 1Q14 Top - line results of PRTX - 100 - 104 trial □ 2Q14 PRTX - 100 glob

  20. Slide 20: Protalex Corporate Highlights

    Protalex Corporate Highlights PRTX - 100 is a novel immunomodulatory biological drug candidate that may be useful in the treatment of autoimmune diseases PRTX - 100 is economical to produce relative to anti - TNFs, anti - IL - 6, and CTL4 - Ig biologicals ; validated manufacturing PRTX - 100 is safe

Protalex — Investor Presentation (September 2013) on 6ix